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S U M M A R Y
Objectives: Extended-spectrum beta-lactamase-expressing Gram-negative bacilli (ESBL-GNB) now
commonly cause community-acquired infections, including urinary tract infections (UTI), and represent
a challenge for practitioners in choosing empirical antibiotics. The aim of this study was to describe the
epidemiology and clinical characteristics of UTIs/bacteriuria due to ESBL-GNB in Australia.
Methods: At a single-site tertiary referral hospital, 100 cases with UTIs/bacteriuria due to ESBL-GNB
were matched to 100 cases where UTIs/bacteriuria were caused by organisms matching the ESBL
bacterial species that had routine susceptibility to antibiotics. Potential risk factors for ESBL-GNB UTI/
bacteriuria and differences in clinical outcomes were identiﬁed.
Results: Length of admission prior to positive sample (odds ratio (OR) 1.3, p = 0.03, per week), exposure
to antibiotics (OR 5.7, p < 0.001), return from overseas travel (OR 6.5, p = 0.002), and nursing home
residency (OR 4.2, p = 0.03) were identiﬁed as risk factors associated with ESBL-GNB UTI/bacteriuria in
the multivariate analysis. In addition, ESBL-GNB-infected cases subsequently had a longer inpatient stay
(median 6 vs. 2 days, p = 0.002) and were admitted to the intensive care unit more frequently (28/100 vs.
8/100, p < 0.001).
Conclusions: Our results emphasize the need for culture of a mid-stream urine specimen prior to
commencing antibacterials, especially in patients with the risk factors identiﬁed herein associated with
ESBL-GNB UTI/bacteriuria.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Increasing resistance to antimicrobials among pathogens that
cause common infections is a problem of great global proportions
given the paucity of novel antibiotics in development. This is
particularly the case for Gram-negative bacteria (GNB) where
antibiotic development faces more substantial challenges than for
Gram-positive organisms, yet antimicrobial resistance is readily
acquired. The newest and gravest challenge among resistant Gram-
negative bacteria is posed by New Delhi metallo-beta-lactamase 1
(NDM-1)-expressing organisms that are resistant to all but highly
toxic antibiotics like colistin.1 These organisms have been found* Corresponding author. Tel.: +61 3 9342 9406; fax: +61 3 9342 7277.
E-mail address: damon.eisen@mh.org.au (D.P. Eisen).
http://dx.doi.org/10.1016/j.ijid.2015.03.006
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).infrequently in Australian patients.2 While less attention grabbing,
a much more prevalent current problem in Australia relates to the
increasing frequency of resistant GNB expressing extended-
spectrum beta-lactamases (ESBL) (http://www.agargroup.org/
surveys). These organisms were ﬁrst recognized as causing
nosocomial infections in Europe in the 1980s3, and in Australia,
they have been associated with hospital outbreaks,4 community
infections,5 and nursing home infections.6 ESBL-expressing GNB
(ESBL-GNB) now commonly cause community-acquired infections,
including urinary tract infections (UTIs).7 As they are frequently
resistant to numerous antibiotic classes, including ﬂuoroquino-
lones and aminoglycosides, these ESBL-GNB represent a challenge
for practitioners in choosing empirical antibiotics where there is a
reasonable likelihood of their presence.
The aim of this study was to highlight the presence of ESBL-GNB
in patients presenting to Australian practitioners based both inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Distribution of Escherichia coli, Proteus mirabilis, and Klebsiella spp cultured from
urine specimens obtained between 2003 and 2009
Organism Positive cultures, n (%) % of total ESBL-positive
Escherichia coli 10 974 (72.5)
ESBL-positive 232 (1.5) 73.4
Klebsiella oxytoca 572 (3.8)
ESBL-positive 10 (0.1) 3.2
Klebsiella pneumoniae 1605 (10.5)
ESBL-positive 74 (0.5) 23.4
Klebsiella spp 17 (0.1)
Proteus mirabilis 1658 (11.0)
Total 15 142 (100) 100
ESBL, extended-spectrum beta-lactamase.
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performed to deﬁne the epidemiology and clinical outcomes of
UTI/bacteriuria due to ESBL-GNB, concentrating on the recognized
risk factors for the acquisition of these organisms. Recommenda-
tions for appropriate antimicrobials can be made in patients
presenting with UTI who are at high risk of infection due to ESBL-
GNB.
2. Methods
2.1. Patients and data collection
A retrospective case–control study was conducted to identify
risk factors associated with community- or hospital-onset UTI/
bacteriuria due to ESBL-producing GNB at the Royal Melbourne
Hospital, a major primary and tertiary care service provider. Urine
samples entered into the administrative database of the microbi-
ology laboratory from January 1, 2003 to December 31, 2009 from
patients aged 18 years or older were evaluated for culture results
positive for urinary pathogens. These patients received either
ambulatory or inpatient care. If multiple urine specimens from the
same patient were available, only the ﬁrst sample was selected for
the analysis. The same patient was only included once as either a
case or a control.
A comprehensive review of medical records and online hospital
databases was performed to retrieve demographic, clinical,
radiographic, and microbiological data. Data collection included
gender, age, all medical diagnoses, hospitalization in the past
4 weeks, overseas travel within the last 12 months, exposure to
antibiotics during the past 6 weeks, living in an aged care facility,
type of urinary sample, antibiotic resistance proﬁle, body
temperature and blood pressure on the day of urine sampling,
and type of urinary tract infection. Outcome variables included
antimicrobial treatment, length of hospital stay and/or admission
to the intensive care unit (ICU) after urine sampling, and all-cause
inpatient mortality.
2.2. Microbiological methods
Gram-negative organisms with antibiotic resistance patterns
indicative of the presence of ESBLs from automated susceptibility
testing (resistance to amoxicillin but susceptibility to amoxicillin–
clavulanate in the presence of resistance to third-generation
cephalosporins using the time period-relevant Clinical and
Laboratory Standards Institute breakpoints8), were conﬁrmed as
ESBL-expressing bacteria by applying a manual method using the
‘keyhole test’. This test, in the past used routinely in Australia and
internationally for this purpose, relies on identifying an increased
zone of microbial inhibition around a third-generation cephalo-
sporin disc in the locale of a clavulanic acid disc. As expected from
previous experience at the Royal Melbourne Hospital and other
centres, the microorganisms that carried ESBLs were Escherichia
coli, Klebsiella oxytoca, or Klebsiella pneumoniae. A total of 316 ESBL-
GNB from 178 patients were present among 15 142 positive urine
cultures examined (Table 1). This analysis was conﬁned to
100 cases that were selected randomly from urine samples with
a signiﬁcant growth of an ESBL-producing organism, taking into
account the relative frequency of all cultured ESBL-producing
bacteria (73 E. coli, 23 K. pneumoniae, and 4 K. oxytoca). We did not
select patients for the presence of symptomatic UTI as we were
interested in assessing the associations between ESBL urinary
colonization in addition to infection. To allow the exploration of
patient characteristics that may distinguish patients with ESBL-
GNB UTI/bacteriuria from those without, controls were matched to
cases in a 1:1 ratio only in relation to the bacterial species causing
the UTI. Controls therefore consisted of randomly selected patientsfrom the same study period displaying signiﬁcant bacteriuria with
a urinary pathogen matched to the ESBL-GNB-producing organism
but that differed by maintaining susceptibility to third-generation
cephalosporins.
2.3. Deﬁnitions
Asymptomatic bacteriuria, cystitis (complicated and uncom-
plicated), pyelonephritis, and urosepsis were deﬁned according to
published guidelines.9 An ESBL-producing organism was consid-
ered multiresistant if it was additionally resistant to all three
classes of the following antimicrobials: ﬂuoroquinolones, trimeth-
oprim–sulfamethoxazole, and aminoglycosides.10
2.4. Statistical analysis
Potential risk factors for ESBL-GNB UTI/bacteriuria were
identiﬁed by univariate analysis. The Chi-square test or Fisher’s
exact test was used for categorical variables, and the Student t-test
or the Mann–Whitney U-test for continuous variables, as
appropriate. All variables that were associated with ESBL-GNB
infection or ICU admission in the univariate analysis at the
p < 0.1 level were included in the logistic regression using the
forward conditional method. Variables were retained in the ﬁnal
model if they were signiﬁcant at the p < 0.05 level. The ﬁnal model
included confounding variables signiﬁcant at a two-tailed p-value
of <0.05. SPSS version 18.0 software package was used for the
analysis (SPSS Inc., Chicago, IL, USA).
3. Results
During the 7-year observation period, E. coli, Proteus mirabilis, or
Klebsiella species were identiﬁed in 15 142 urine samples from
10 111 patients, including 316 (2.1%) specimens with an ESBL-GNB
from 178 patients (Table 1). Samples were midstream specimens in
80% of controls and 57% of cases. Distinct clinical and microbio-
logical features of UTI were only present in 40% of both cases and
controls, with the remaining subjects being classiﬁed as suffering
from asymptomatic bacteriuria. Among the patients who were
treated, 50/58 cases and 53/54 controls (difference not signiﬁcant)
received appropriate directed antibiotic treatment.
Differences in risk factors and outcomes for cases and controls
are displayed in Table 2 (univariate analysis). The length of hospital
stay prior to the urine sampling episode analyzed here was
signiﬁcantly longer in cases than in controls (p < 0.001). In
addition, exposure to antibiotics in the past 6 weeks and recent
return from overseas travel, mainly to Asia, were identiﬁed as
signiﬁcant risk factors associated with UTI due to ESBL-GNB.
Interestingly, the frequencies of major comorbidities such as
diabetes or cancer and of past UTIs were not signiﬁcantly different
between cases and controls.
Table 2
Univariate analysis of risk factors and outcomes for ESBL-GNB UTI/bacteriuriaa





Male, n 28 23 0.4
Age in years, mean (SD) 61.6 (22.4) 60 (20.9) 0.6
Hospitalization in previous month, n 17 12 0.4
Length of stay prior to positive sample in days, median (IQR) 5.5 (0–27) 0 (0–3) <0.0001
Diabetes mellitus, n 22 23 0.9
Cancer/immunosuppression, n 23 24 0.8
Nursing home residency, n 10 4 0.1
Prostatism, n 7 8 1
Overseas travel in past 12 months 15 5 0.03
Asia 9 2 0.06
Other destinations 6 3 0.5
Exposure to antibiotics in past 6 weeks, n 70 27 <0.001
1 class 24 17 0.3
2 classes 20 8 0.02
>2 classes 26 2 <0.001
Third-generation cephalosporins 21 2 <0.001
Vancomycin 15 3 0.002
Previous UTI episodes, n 40 39 1
Duration of hospitalization after sampling in days, median (IQR) 6 (2–16) 2 (0–9) 0.002
Duration of treatment in days, median (IQR) 7 (0–10) 5 (0–7) 0.1
Admission to ICU, n 28 8 <0.001
All-cause mortality, n 8 4 0.4
ESBL-GNB, extended-spectrum beta-lactamase-expressing Gram-negative bacilli; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation; UTI, urinary tract
infection.
a Data are given as number of subjects which equals percentage.
M. Osthoff et al. / International Journal of Infectious Diseases 34 (2015) 79–83 81Regarding outcomes after infection (Table 2), the median
duration of stay after the diagnosis of UTI was three times longer in
cases than in controls, as was the overall admission period (data
not shown). This outcome was certainly inﬂuenced by the fact that
almost 50% of cases were inpatients at the time of urine sampling
compared to only 16% of controls. ESBL-GNB-infected cases were
more likely to be admitted subsequently to the ICU for any reason
than controls with a UTI due to the same organisms with routine
susceptibility (Table 2). However, there was no difference in
inpatient all-cause mortality between cases and controls, although
there were few deaths overall.
As expected, ESBL-producing urinary pathogens were signiﬁ-
cantly more often resistant to non-beta-lactam antibiotics, and
27% of the isolates were classiﬁed as multidrug-resistant.
However, susceptibility to carbapenems (100%) and nitrofurantoin
(84%) was retained in the majority of ESBL-GNB isolates causing
UTIs/bacteriuria (Table 3).
On multivariate analysis, previous overseas travel, recent
exposure to antibiotics, residency in a nursing home, and longer
hospitalization prior to positive sample were identiﬁed as
independent risk factors in cases, with odds ratios between
1.2 and 6.5 (Table 4).Table 3
Microbiological characteristicsa





Ciproﬂoxacin, n (%) 140 (70) 40 100 <0.001
Trimethoprim, n (%) 99 (45.5) 20 79 <0.001
TMP–SMX, n (%) 106 (53) 24 82 <0.001
Gentamicin, n (%) 154 (77) 54 100 <0.001
Nitrofurantoin, n (%) 169 (84.5) 84 85 1
Meropenem, n (%) 200 (100) 100 100 1
Multidrug resistanceb, n (%) 27 (13.5) 27 0 <0.001
TMP–SMX, trimethoprim–sulfamethoxazole.
a Data are given as the number of subjects, which equals the percentage for cases
and controls.
b Multidrug resistance was deﬁned as combined resistance to ﬂuoroquinolones,
aminoglycosides, and trimethoprim–sulfamethoxazole.4. Discussion
Recent travel, previous exposure to antibiotics, residency in a
nursing home, and length of hospital inpatient stay were found to
be the factors associated with ESBL-GNB UTI at an Australian
tertiary referral hospital during 2003 to 2009. Patients with ESBL-
GNB were more likely to require ICU admission and had longer
inpatient stays than those with organisms of the same species that
had routine susceptibilities. Given the fact that only 40% of cases
and controls suffered from a symptomatic UTI, these ﬁndings are
even more remarkable. Asymptomatic urinary tract colonization
might predispose to subsequent invasive infection with ESBL-GNB.
Interestingly, previous studies that have described a signiﬁcantly
increased risk for invasive infection with an ESBL-GNB in patients
with rectal colonization, did not screen for urinary tract
colonization11,12. However, a recent study clearly showed that
the urinary tract is actually a very frequent colonization site, and
that more than 20% of patients will be missed if screening relies
only on rectal swabs.13 Australian data on rectal colonization with
multidrug-resistant organisms in returning travelers14 and aged
care facility residents6 have previously been reported, but the
present study is the ﬁrst to examine risk factors for ESBL-GNB
UTI/colonization in Australian residents.Table 4
Multivariate analysis of risk factors associated with ESBL-GNB UTI/bacteriuria and
with admission to the ICU
Variable OR 95% CI p-Value
ESBL-GNB UTI/bacteriuria
Length of stay prior to positive sample 1.2a 1.0–1.3 0.03
Nursing home residency 4.2 1.1–15.7 0.03
Overseas travel in past 12 months 6.5 2.0–20.9 0.002
Exposure to antibiotics in past 6 weeks 5.7 2.8–11.6 <0.001
ICU admission
Diabetes mellitus 0.3 0.1–0.9 0.03
ESBL-GNB UTI/bacteriuria 4.6 2.0–10.8 <0.001
CI, conﬁdence interval; ESBL-GNB, extended-spectrum beta-lactamase-expressing
Gram-negative bacilli; ICU, intensive care unit; OR, odds ratio; UTI, urinary tract
infection.
a Per week of hospitalization.
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with ESBL-GNB UTI in studies performed in European coun-
tries.15,16 In these settings though, the effect of international travel
is harder to quantify due to the widespread community prevalence
of ESBL-GNB. Australian patients are clearly part of the global
community, with the negative consequences of travel-associated
acquisition of ESBL-GNB evident. Indeed, recent studies have
shown prolonged enteric carriage of ESBL-GNB in returned
Australian and Swedish travelers.17,18 Whereas gastrointestinal
colonization with multidrug-resistant organisms in repatriated
patients is often anticipated and screened for,19 clinicians are less
vigilant about the possibility of multidrug-resistant organisms in
patients presenting from the community who have not travelled in
the past. Risk factors for ESBL-GNB UTI/bacteriuria identiﬁed in the
present study will help to guide doctors in recognizing patients at
high risk of infection/colonization due to these organisms.
Previous exposure to antibiotics has been identiﬁed as a risk
factor for ESBL-GNB infection in multiple studies,15,20 which
clearly underscores the ongoing rationale for responsible use of
antibiotics. Our ﬁndings of an increased length of stay and more
frequent ICU admission in patients with ESBL-GNB compared to
non-ESBL-GNB are consistent with evidence from previous
studies21,22 and highlight the increased burden of disease
associated with resistant bacteria.
The frequency of resistance to antibiotics routinely used for UTI
in this series of ESBL-GNB, emphasizes the need for culture of a
mid-stream urine specimen prior to commencing antibiotics in
patients with the risk factors identiﬁed herein. Studies such as
these must be used to guide appropriate antibacterial therapy for
patients at risk of ESBL-GNB. The majority (84%) of the ESBL-GNB
organisms causing UTI at the Royal Melbourne Hospital during the
period studied retained susceptibility to nitrofurantoin, which is
among the choices for initial therapy of cystitis listed by the
Australian Antimicrobial guidelines23 and is clearly an appropriate
initial therapy for a well patient with lower tract symptoms of UTI,
even if they are at risk of ESBL-GNB infection. Where a patient has
cystitis due to an ESBL-GNB that is resistant to nitrofurantoin,
ﬂuoroquinolones, and trimethoprim and where they remain well,
the options for outpatient-based oral antibiotic therapy are limited
to fosfomycin,24 which is not licensed in Australia at the present
and therefore is available only via a special access scheme. Thus
these patients require hospital assessment and prescription of this
antibiotic. Patients who are unwell with pyelonephritis due to
ESBL-GNB require therapy with an intravenous meropenem,
which, while thankfully retaining activity against all multi-
resistant organisms in this study, is not an ideal agent due to its
broad spectrum and relative instability that complicates hospital
in the home (HITH) therapy.25 Where the ESBL-GNB is susceptible,
patients may be treated through HITH with the once-daily
carbapenem drug ertapenem.26
Even more challenging are the patients with recurrent ESBL-
GNB UTI. These patients are often prescribed long-term nitrofur-
antoin,27 but the organism frequently develops resistance to this
mainstay antibiotic, which has toxicity in long-term use28 and
must not be used where patients have renal impairment. Apart
from investigating and correcting structural urological abnormali-
ties, repeated courses of fosfomycin may be used, although there is
little evidence to support this therapy. Falling back on old-
fashioned approaches to urinary antisepsis using methenamine
hippurate may be required, which has been shown to be useful for
preventing UTI in patients without renal tract abnormalities in a
recent Cochrane review.29
Our study has limitations, including the retrospective nature,
the limited matching, and the inclusion of urine samples from both
hospitalized and ambulatory patients, which might be associated
with signiﬁcant bias. The small sample size might have preventedthe identiﬁcation of additional risk factors for ESBL-GNB UTI/
bacteriuria. In addition, the majority of cases and controls did not
show evidence of infection but only colonization.
In summary, we have identiﬁed risk factors for UTI/colonization
with ESBL-GNB in an Australian tertiary care centre to guide
doctors in recognizing the patients at high risk of infections due to
these organisms. Our results emphasize the need for culture of a
mid-stream urine specimen prior to commencing antibiotics,
especially in patients with the risk factors identiﬁed herein
associated with ESBL-GNB UTI. Australia could never have hoped to
be able to close its borders, so to speak, to the bacteria of the globe,
and we have not been spared an increase in infections due to
ESBL-GNB. Yet again, we are reminded of the need to carefully
protect the antibiotics we currently have available and push for the
discovery of new ones for the future.
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